Autoimmune hemolytic anemia and COVID-19 vaccination

Jacobs, Jeremy W

doi:10.1016/j.htct.2022.08.007

Cited by 1 publication

(2 citation statements)

References 7 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the mounting reports of these life-threatening sequelae are alarming, and further investigation of the underlying pathophysiology as well as adverse event monitoring and correlation with phenotypic associations are needed. Notably, we did not identify any reports of AIHA, thrombotic thrombocytopenic purpura, or acquired coagulation factor inhibitors in the VAERS database, all of which have been reported in association with the original formulations of the Pfizer-BioNTech and Moderna vaccines [6,7,12,13]. However, we acknowledge that one limitation of VAERS is that it is a passive reporting system, which may contribute to underreporting, therefore biasing the calculated rate and prevalence of reported conditions.…”

Section: Discussionmentioning

confidence: 93%

“…While observed following all vaccine types, VITT is most commonly associated with the Ad26.COV2.S (Johnson & Johnson/Janssen) and ChAdOx1 nCoV-19 (AstraZeneca) adenoviral vector vaccines [4]. ITP [5] and AIHA [6,7] have also been reported following SARS-CoV-2 vaccination, including among patients vaccinated with the mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines at low rates.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination

2023

Self Cite

View full text Add to dashboard Cite

Hematologic complications, including vaccine-induced immune thrombotic thrombocytopenia (VITT), immune thrombocytopenia (ITP), and autoimmune hemolytic anemia (AIHA), have been associated with the original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. However, on August 31, 2022, new formulations of the Pfizer-BioNTech and Moderna vaccines were approved for use without clinical trial testing. Thus, any potential adverse hematologic effects with these new vaccines remain unknown. We queried the US Centers for Disease Control Vaccine Adverse Event Reporting System (VAERS), a national surveillance database, through February 3, 2023, all reported hematologic adverse events that occurred within 42 days of administration of either the Pfizer-BioNTech or Moderna Bivalent COVID-19 Booster vaccine. We included all patient ages and geographic locations and utilized 71 unique VAERS diagnostic codes pertaining to a hematologic condition as defined in the VAERS database. Fifty-five reports of hematologic events were identified (60.0% Pfizer-BioNTech, 27.3% Moderna, 7.3% Pfizer-BioNTech bivalent booster plus influenza, 5.5% Moderna bivalent booster plus influenza). The median age of patients was 66 years, and 90.9% (50/55) of reports involved a description of cytopenias or thrombosis. Notably, 3 potential cases of ITP and 1 case of VITT were identified. In one of the first safety analyses of the new SARS-CoV-2 booster vaccines, we identified few adverse hematologic events (1.05 per 1,000,000 doses), most of which could not be definitively attributed to vaccination. However, three reports of possible ITP and one report of possible VITT highlight the need for continued safety monitoring of these vaccines as their use expands and new formulations are authorized. KeywordsCOVID-19 • SARS-CoV-2 • Bivalent vaccine • Autoimmune hemolytic anemia • Immune thrombocytopenia • Vaccine-induced immune thrombotic thrombocytopenia * Jeremy W. Jacobs

show abstract

Section: Discussionmentioning

confidence: 93%